BR112023025986A2 - Compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5 - Google Patents

Compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5

Info

Publication number
BR112023025986A2
BR112023025986A2 BR112023025986A BR112023025986A BR112023025986A2 BR 112023025986 A2 BR112023025986 A2 BR 112023025986A2 BR 112023025986 A BR112023025986 A BR 112023025986A BR 112023025986 A BR112023025986 A BR 112023025986A BR 112023025986 A2 BR112023025986 A2 BR 112023025986A2
Authority
BR
Brazil
Prior art keywords
prmt5
prevention
treatment
mediated disorder
compounds useful
Prior art date
Application number
BR112023025986A
Other languages
English (en)
Inventor
Andrew Morley
La Thangue Nicholas
Shonagh Munro
Original Assignee
Argonaut Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argonaut Therapeutics Ltd filed Critical Argonaut Therapeutics Ltd
Publication of BR112023025986A2 publication Critical patent/BR112023025986A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5. a presente revelação está relacionada aos compostos adequados para a inibição de proteína arginina metil-transferase (prmt), em particular prmt5. esses compostos podem ser para uso como agentes terapêuticos, em particular, agentes para uso no tratamento e/ou prevenção de doenças proliferativas como, por exemplo, câncer.
BR112023025986A 2021-06-11 2022-06-10 Compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5 BR112023025986A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108383.7A GB202108383D0 (en) 2021-06-11 2021-06-11 Compounds useful in the treatment or prevention of a prmt5-mediated disorder
PCT/GB2022/051462 WO2022258986A1 (en) 2021-06-11 2022-06-10 Compounds useful in the treatment or prevention of a prmt5-mediated disorder

Publications (1)

Publication Number Publication Date
BR112023025986A2 true BR112023025986A2 (pt) 2024-02-27

Family

ID=76954398

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025986A BR112023025986A2 (pt) 2021-06-11 2022-06-10 Compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5

Country Status (11)

Country Link
US (1) US20240287036A1 (pt)
EP (1) EP4352048A1 (pt)
JP (1) JP2024521431A (pt)
KR (1) KR20240035415A (pt)
CN (1) CN117480162A (pt)
AU (1) AU2022290645A1 (pt)
BR (1) BR112023025986A2 (pt)
GB (1) GB202108383D0 (pt)
IL (1) IL309002A (pt)
MX (1) MX2023014669A (pt)
WO (1) WO2022258986A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024084360A1 (en) * 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2194181T3 (es) 1996-02-13 2003-11-16 Astrazeneca Ab Derivados de quinazolina como inhibidores de vegf.
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
RU2262935C2 (ru) 1999-02-10 2005-10-27 Астразенека Аб Производные хиназолина в качестве ингибиторов ангиогенеза
US7030123B2 (en) 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU6623201A (en) 2000-07-07 2002-02-05 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
EP3160466A4 (en) * 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
GB201704327D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
CN117480162A (zh) 2024-01-30
EP4352048A1 (en) 2024-04-17
IL309002A (en) 2024-01-01
GB202108383D0 (en) 2021-07-28
MX2023014669A (es) 2024-01-12
US20240287036A1 (en) 2024-08-29
KR20240035415A (ko) 2024-03-15
JP2024521431A (ja) 2024-05-31
AU2022290645A1 (en) 2024-01-18
WO2022258986A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
BR112019023758A2 (pt) vírus da doença newcastle e seus usos
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112014026801A2 (pt) 5-[[4-[[morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazina-2-carbonitrila e usos terapêuticos do mesmo
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
BR112022025550A2 (pt) Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
BR112023025986A2 (pt) Compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5
BR112022008164A2 (pt) Terapia de combinação para tratar câncer cerebral
BR112019011350A2 (pt) terapia de combinação
CO2022000270A2 (es) Inhibidores de enzimas
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody